Cargando…

Cellular dosimetry of [(177)Lu]Lu-DOTA-[Tyr(3)]octreotate radionuclide therapy: the impact of modeling assumptions on the correlation with in vitro cytotoxicity

BACKGROUND: Survival and linear-quadratic model fitting parameters implemented in treatment planning for targeted radionuclide therapy depend on accurate cellular dosimetry. Therefore, we have built a refined cellular dosimetry model for [(177)Lu]Lu-DOTA-[Tyr(3)]octreotate ((177)Lu-DOTATATE) in vitr...

Descripción completa

Detalles Bibliográficos
Autores principales: Tamborino, Giulia, De Saint-Hubert, Marijke, Struelens, Lara, Seoane, Dayana C., Ruigrok, Eline A. M., Aerts, An, van Cappellen, Wiggert A., de Jong, Marion, Konijnenberg, Mark W., Nonnekens, Julie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7010903/
https://www.ncbi.nlm.nih.gov/pubmed/32040783
http://dx.doi.org/10.1186/s40658-020-0276-5
_version_ 1783495963375042560
author Tamborino, Giulia
De Saint-Hubert, Marijke
Struelens, Lara
Seoane, Dayana C.
Ruigrok, Eline A. M.
Aerts, An
van Cappellen, Wiggert A.
de Jong, Marion
Konijnenberg, Mark W.
Nonnekens, Julie
author_facet Tamborino, Giulia
De Saint-Hubert, Marijke
Struelens, Lara
Seoane, Dayana C.
Ruigrok, Eline A. M.
Aerts, An
van Cappellen, Wiggert A.
de Jong, Marion
Konijnenberg, Mark W.
Nonnekens, Julie
author_sort Tamborino, Giulia
collection PubMed
description BACKGROUND: Survival and linear-quadratic model fitting parameters implemented in treatment planning for targeted radionuclide therapy depend on accurate cellular dosimetry. Therefore, we have built a refined cellular dosimetry model for [(177)Lu]Lu-DOTA-[Tyr(3)]octreotate ((177)Lu-DOTATATE) in vitro experiments, accounting for specific cell morphologies and sub-cellular radioactivity distributions. METHODS: Time activity curves were measured and modeled for medium, membrane-bound, and internalized activity fractions over 6 days. Clonogenic survival assays were performed at various added activities (0.1–2.5 MBq/ml). 3D microscopy images (stained for cytoplasm, nucleus, and Golgi) were used as reference for developing polygonal meshes (PM) in 3DsMax to accurately render the cellular and organelle geometry. Absorbed doses to the nucleus per decay (S values) were calculated for 3 cellular morphologies: spheres (MIRDcell), truncated cone-shaped constructive solid geometry (CSG within MCNP6.1), and realistic PM models, using Geant4-10.03. The geometrical set-up of the clonogenic survival assays was modeled, including dynamic changes in proliferation, proximity variations, and cell death. The absorbed dose to the nucleus by the radioactive source cell (self-dose) and surrounding source cells (cross-dose) was calculated applying the MIRD formalism. Finally, the correlation between absorbed dose and survival fraction was fitted using a linear dose-response curve (high α/β or fast sub-lethal damage repair half-life) for different assumptions, related to cellular shape and localization of the internalized fraction of activity. RESULTS: The cross-dose, depending on cell proximity and colony formation, is a minor (15%) contributor to the total absorbed dose. Cellular volume (inverse exponential trend), shape modeling (up to 65%), and internalized source localization (up to + 149% comparing cytoplasm to Golgi) significantly influence the self-dose to nucleus. The absorbed dose delivered to the nucleus during a clonogenic survival assay is 3-fold higher with MIRDcell compared to the polygonal mesh structures. Our cellular dosimetry model indicates that (177)Lu-DOTATATE treatment might be more effective than suggested by average spherical cell dosimetry, predicting a lower absorbed dose for the same cellular survival. Dose-rate effects and heterogeneous dose delivery might account for differences in dose-response compared to x-ray irradiation. CONCLUSION: Our results demonstrate that modeling of cellular and organelle geometry is crucial to perform accurate in vitro dosimetry.
format Online
Article
Text
id pubmed-7010903
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-70109032020-02-25 Cellular dosimetry of [(177)Lu]Lu-DOTA-[Tyr(3)]octreotate radionuclide therapy: the impact of modeling assumptions on the correlation with in vitro cytotoxicity Tamborino, Giulia De Saint-Hubert, Marijke Struelens, Lara Seoane, Dayana C. Ruigrok, Eline A. M. Aerts, An van Cappellen, Wiggert A. de Jong, Marion Konijnenberg, Mark W. Nonnekens, Julie EJNMMI Phys Original Research BACKGROUND: Survival and linear-quadratic model fitting parameters implemented in treatment planning for targeted radionuclide therapy depend on accurate cellular dosimetry. Therefore, we have built a refined cellular dosimetry model for [(177)Lu]Lu-DOTA-[Tyr(3)]octreotate ((177)Lu-DOTATATE) in vitro experiments, accounting for specific cell morphologies and sub-cellular radioactivity distributions. METHODS: Time activity curves were measured and modeled for medium, membrane-bound, and internalized activity fractions over 6 days. Clonogenic survival assays were performed at various added activities (0.1–2.5 MBq/ml). 3D microscopy images (stained for cytoplasm, nucleus, and Golgi) were used as reference for developing polygonal meshes (PM) in 3DsMax to accurately render the cellular and organelle geometry. Absorbed doses to the nucleus per decay (S values) were calculated for 3 cellular morphologies: spheres (MIRDcell), truncated cone-shaped constructive solid geometry (CSG within MCNP6.1), and realistic PM models, using Geant4-10.03. The geometrical set-up of the clonogenic survival assays was modeled, including dynamic changes in proliferation, proximity variations, and cell death. The absorbed dose to the nucleus by the radioactive source cell (self-dose) and surrounding source cells (cross-dose) was calculated applying the MIRD formalism. Finally, the correlation between absorbed dose and survival fraction was fitted using a linear dose-response curve (high α/β or fast sub-lethal damage repair half-life) for different assumptions, related to cellular shape and localization of the internalized fraction of activity. RESULTS: The cross-dose, depending on cell proximity and colony formation, is a minor (15%) contributor to the total absorbed dose. Cellular volume (inverse exponential trend), shape modeling (up to 65%), and internalized source localization (up to + 149% comparing cytoplasm to Golgi) significantly influence the self-dose to nucleus. The absorbed dose delivered to the nucleus during a clonogenic survival assay is 3-fold higher with MIRDcell compared to the polygonal mesh structures. Our cellular dosimetry model indicates that (177)Lu-DOTATATE treatment might be more effective than suggested by average spherical cell dosimetry, predicting a lower absorbed dose for the same cellular survival. Dose-rate effects and heterogeneous dose delivery might account for differences in dose-response compared to x-ray irradiation. CONCLUSION: Our results demonstrate that modeling of cellular and organelle geometry is crucial to perform accurate in vitro dosimetry. Springer International Publishing 2020-02-10 /pmc/articles/PMC7010903/ /pubmed/32040783 http://dx.doi.org/10.1186/s40658-020-0276-5 Text en © The Author(s). 2020 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research
Tamborino, Giulia
De Saint-Hubert, Marijke
Struelens, Lara
Seoane, Dayana C.
Ruigrok, Eline A. M.
Aerts, An
van Cappellen, Wiggert A.
de Jong, Marion
Konijnenberg, Mark W.
Nonnekens, Julie
Cellular dosimetry of [(177)Lu]Lu-DOTA-[Tyr(3)]octreotate radionuclide therapy: the impact of modeling assumptions on the correlation with in vitro cytotoxicity
title Cellular dosimetry of [(177)Lu]Lu-DOTA-[Tyr(3)]octreotate radionuclide therapy: the impact of modeling assumptions on the correlation with in vitro cytotoxicity
title_full Cellular dosimetry of [(177)Lu]Lu-DOTA-[Tyr(3)]octreotate radionuclide therapy: the impact of modeling assumptions on the correlation with in vitro cytotoxicity
title_fullStr Cellular dosimetry of [(177)Lu]Lu-DOTA-[Tyr(3)]octreotate radionuclide therapy: the impact of modeling assumptions on the correlation with in vitro cytotoxicity
title_full_unstemmed Cellular dosimetry of [(177)Lu]Lu-DOTA-[Tyr(3)]octreotate radionuclide therapy: the impact of modeling assumptions on the correlation with in vitro cytotoxicity
title_short Cellular dosimetry of [(177)Lu]Lu-DOTA-[Tyr(3)]octreotate radionuclide therapy: the impact of modeling assumptions on the correlation with in vitro cytotoxicity
title_sort cellular dosimetry of [(177)lu]lu-dota-[tyr(3)]octreotate radionuclide therapy: the impact of modeling assumptions on the correlation with in vitro cytotoxicity
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7010903/
https://www.ncbi.nlm.nih.gov/pubmed/32040783
http://dx.doi.org/10.1186/s40658-020-0276-5
work_keys_str_mv AT tamborinogiulia cellulardosimetryof177luludotatyr3octreotateradionuclidetherapytheimpactofmodelingassumptionsonthecorrelationwithinvitrocytotoxicity
AT desainthubertmarijke cellulardosimetryof177luludotatyr3octreotateradionuclidetherapytheimpactofmodelingassumptionsonthecorrelationwithinvitrocytotoxicity
AT struelenslara cellulardosimetryof177luludotatyr3octreotateradionuclidetherapytheimpactofmodelingassumptionsonthecorrelationwithinvitrocytotoxicity
AT seoanedayanac cellulardosimetryof177luludotatyr3octreotateradionuclidetherapytheimpactofmodelingassumptionsonthecorrelationwithinvitrocytotoxicity
AT ruigrokelineam cellulardosimetryof177luludotatyr3octreotateradionuclidetherapytheimpactofmodelingassumptionsonthecorrelationwithinvitrocytotoxicity
AT aertsan cellulardosimetryof177luludotatyr3octreotateradionuclidetherapytheimpactofmodelingassumptionsonthecorrelationwithinvitrocytotoxicity
AT vancappellenwiggerta cellulardosimetryof177luludotatyr3octreotateradionuclidetherapytheimpactofmodelingassumptionsonthecorrelationwithinvitrocytotoxicity
AT dejongmarion cellulardosimetryof177luludotatyr3octreotateradionuclidetherapytheimpactofmodelingassumptionsonthecorrelationwithinvitrocytotoxicity
AT konijnenbergmarkw cellulardosimetryof177luludotatyr3octreotateradionuclidetherapytheimpactofmodelingassumptionsonthecorrelationwithinvitrocytotoxicity
AT nonnekensjulie cellulardosimetryof177luludotatyr3octreotateradionuclidetherapytheimpactofmodelingassumptionsonthecorrelationwithinvitrocytotoxicity